Silencing RORγt in Human CD4+ T cells with CD30 aptamer-RORγt shRNA Chimera

Xiaofei Shi, Pingfang Song, Shao Tao, Xiaowei Zhang, Cong-Qiu Chu

Research output: Contribution to journalArticle

Abstract

Targeting specific T cell subtypes and intervening in their function are emerging a critical strategy for treatment of autoimmune diseases. Here we report that an RNA CD30 aptamer was utilized to deliver short hairpin RNA (shRNA) to CD30+ T cells to target retinoic acid receptor-related orphan receptor gamma t (RORγt), leading to impaired expression of RORγt and suppression of IL-17A and IL-17F. A DNA template consisting of CD30 aptamer and RORγt shRNA sequences was synthesized and was transcribed CD30 aptamer-RORγt shRNA chimera (CD30-AshR-RORγt). Insertion of 2′-F-dCTP and 2′-FdUTP was incorporated during CD30-AshR-RORγt transcription to increase its resistance to RNase. CD30-AshR-RORγt was specifically up-taken by CD30+ Karpas 299 cells, but not by Jurkat cells which lack CD30. It was also up-taken by activated, CD30 expressing human CD4+T cells, but not by resting CD4+ T cells. The RORγt shRNA moiety of CD30-AshR-RORγt chimera was cleaved and released by Dicers. Then, CD30-AshR-RORγt suppressed RORγt gene expression in Karpas 299 cells and activated human CD4+ T cells. Consistently, silence of Th17 cell differentiation and IL-17A and IL-17F synthesis with CD30-AshR-RORγt was demonstrated in activated human CD4+ T cells from healthy donors and RA patients. CD30-AshR-negative control chimera and prostate specific membrane antigen (PSMA)-AshR-RORγt had no significant impact on the expression of RORγt or IL-17A and IL-17F. These data present a novel strategy for shRNA delivery using CD30 RNA aptamers to down-regulate CD30+ Th17 cells and can be developed as a targeted therapy for treating Th17 cell mediated conditions.

Original languageEnglish (US)
Article number10375
JournalScientific Reports
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Interleukin-17
Small Interfering RNA
T-Lymphocytes
Th17 Cells
Nucleotide Aptamers
Retinoic Acid Receptors
Jurkat Cells
Ribonucleases
Autoimmune Diseases
Cell Differentiation
Down-Regulation
Tissue Donors
Gene Expression
DNA
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Silencing RORγt in Human CD4+ T cells with CD30 aptamer-RORγt shRNA Chimera. / Shi, Xiaofei; Song, Pingfang; Tao, Shao; Zhang, Xiaowei; Chu, Cong-Qiu.

In: Scientific Reports, Vol. 9, No. 1, 10375, 01.12.2019.

Research output: Contribution to journalArticle

Shi, Xiaofei ; Song, Pingfang ; Tao, Shao ; Zhang, Xiaowei ; Chu, Cong-Qiu. / Silencing RORγt in Human CD4+ T cells with CD30 aptamer-RORγt shRNA Chimera. In: Scientific Reports. 2019 ; Vol. 9, No. 1.
@article{6172e34b8202476ea8732f2e7bae6e25,
title = "Silencing RORγt in Human CD4+ T cells with CD30 aptamer-RORγt shRNA Chimera",
abstract = "Targeting specific T cell subtypes and intervening in their function are emerging a critical strategy for treatment of autoimmune diseases. Here we report that an RNA CD30 aptamer was utilized to deliver short hairpin RNA (shRNA) to CD30+ T cells to target retinoic acid receptor-related orphan receptor gamma t (RORγt), leading to impaired expression of RORγt and suppression of IL-17A and IL-17F. A DNA template consisting of CD30 aptamer and RORγt shRNA sequences was synthesized and was transcribed CD30 aptamer-RORγt shRNA chimera (CD30-AshR-RORγt). Insertion of 2′-F-dCTP and 2′-FdUTP was incorporated during CD30-AshR-RORγt transcription to increase its resistance to RNase. CD30-AshR-RORγt was specifically up-taken by CD30+ Karpas 299 cells, but not by Jurkat cells which lack CD30. It was also up-taken by activated, CD30 expressing human CD4+T cells, but not by resting CD4+ T cells. The RORγt shRNA moiety of CD30-AshR-RORγt chimera was cleaved and released by Dicers. Then, CD30-AshR-RORγt suppressed RORγt gene expression in Karpas 299 cells and activated human CD4+ T cells. Consistently, silence of Th17 cell differentiation and IL-17A and IL-17F synthesis with CD30-AshR-RORγt was demonstrated in activated human CD4+ T cells from healthy donors and RA patients. CD30-AshR-negative control chimera and prostate specific membrane antigen (PSMA)-AshR-RORγt had no significant impact on the expression of RORγt or IL-17A and IL-17F. These data present a novel strategy for shRNA delivery using CD30 RNA aptamers to down-regulate CD30+ Th17 cells and can be developed as a targeted therapy for treating Th17 cell mediated conditions.",
author = "Xiaofei Shi and Pingfang Song and Shao Tao and Xiaowei Zhang and Cong-Qiu Chu",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-46855-9",
language = "English (US)",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Silencing RORγt in Human CD4+ T cells with CD30 aptamer-RORγt shRNA Chimera

AU - Shi, Xiaofei

AU - Song, Pingfang

AU - Tao, Shao

AU - Zhang, Xiaowei

AU - Chu, Cong-Qiu

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Targeting specific T cell subtypes and intervening in their function are emerging a critical strategy for treatment of autoimmune diseases. Here we report that an RNA CD30 aptamer was utilized to deliver short hairpin RNA (shRNA) to CD30+ T cells to target retinoic acid receptor-related orphan receptor gamma t (RORγt), leading to impaired expression of RORγt and suppression of IL-17A and IL-17F. A DNA template consisting of CD30 aptamer and RORγt shRNA sequences was synthesized and was transcribed CD30 aptamer-RORγt shRNA chimera (CD30-AshR-RORγt). Insertion of 2′-F-dCTP and 2′-FdUTP was incorporated during CD30-AshR-RORγt transcription to increase its resistance to RNase. CD30-AshR-RORγt was specifically up-taken by CD30+ Karpas 299 cells, but not by Jurkat cells which lack CD30. It was also up-taken by activated, CD30 expressing human CD4+T cells, but not by resting CD4+ T cells. The RORγt shRNA moiety of CD30-AshR-RORγt chimera was cleaved and released by Dicers. Then, CD30-AshR-RORγt suppressed RORγt gene expression in Karpas 299 cells and activated human CD4+ T cells. Consistently, silence of Th17 cell differentiation and IL-17A and IL-17F synthesis with CD30-AshR-RORγt was demonstrated in activated human CD4+ T cells from healthy donors and RA patients. CD30-AshR-negative control chimera and prostate specific membrane antigen (PSMA)-AshR-RORγt had no significant impact on the expression of RORγt or IL-17A and IL-17F. These data present a novel strategy for shRNA delivery using CD30 RNA aptamers to down-regulate CD30+ Th17 cells and can be developed as a targeted therapy for treating Th17 cell mediated conditions.

AB - Targeting specific T cell subtypes and intervening in their function are emerging a critical strategy for treatment of autoimmune diseases. Here we report that an RNA CD30 aptamer was utilized to deliver short hairpin RNA (shRNA) to CD30+ T cells to target retinoic acid receptor-related orphan receptor gamma t (RORγt), leading to impaired expression of RORγt and suppression of IL-17A and IL-17F. A DNA template consisting of CD30 aptamer and RORγt shRNA sequences was synthesized and was transcribed CD30 aptamer-RORγt shRNA chimera (CD30-AshR-RORγt). Insertion of 2′-F-dCTP and 2′-FdUTP was incorporated during CD30-AshR-RORγt transcription to increase its resistance to RNase. CD30-AshR-RORγt was specifically up-taken by CD30+ Karpas 299 cells, but not by Jurkat cells which lack CD30. It was also up-taken by activated, CD30 expressing human CD4+T cells, but not by resting CD4+ T cells. The RORγt shRNA moiety of CD30-AshR-RORγt chimera was cleaved and released by Dicers. Then, CD30-AshR-RORγt suppressed RORγt gene expression in Karpas 299 cells and activated human CD4+ T cells. Consistently, silence of Th17 cell differentiation and IL-17A and IL-17F synthesis with CD30-AshR-RORγt was demonstrated in activated human CD4+ T cells from healthy donors and RA patients. CD30-AshR-negative control chimera and prostate specific membrane antigen (PSMA)-AshR-RORγt had no significant impact on the expression of RORγt or IL-17A and IL-17F. These data present a novel strategy for shRNA delivery using CD30 RNA aptamers to down-regulate CD30+ Th17 cells and can be developed as a targeted therapy for treating Th17 cell mediated conditions.

UR - http://www.scopus.com/inward/record.url?scp=85069445663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069445663&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-46855-9

DO - 10.1038/s41598-019-46855-9

M3 - Article

C2 - 31316164

AN - SCOPUS:85069445663

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 10375

ER -